vimarsana.com
Home
Live Updates
COMMENTARY: Adjuvant vs Neoadjuvant for Resectable NSCLC? :
COMMENTARY: Adjuvant vs Neoadjuvant for Resectable NSCLC? :
COMMENTARY: Adjuvant vs Neoadjuvant for Resectable NSCLC?
Which is better? Concurrent neoadjuvant chemotherapy and immunotherapy or concurrent adjuvant chemotherapy with immunotherapy for non–small cell lung cancer (NSCLC)?
Related Keywords
United States ,
American ,
,
American Society Of Clinical Oncology ,
European Society For Medical Oncology ,
American Society ,
Clinical Oncology ,
Lancet Oncology ,
New England Journal ,
European Society ,
Medical Oncology ,
Patient Presents With Resectable ,
Lung Cancer ,
Ung Carcinoma ,
Ancer Lung ,
Chemotherapy ,
Non Small Cell Lung Cancer ,
Nsclc ,
Neoplasm ,
Tumor ,
Adjuvant Chemotherapy ,
Neoadjuvant ,
Biologic Therapy ,
Immunotherapy ,
Surgery ,
Clinical Research ,
Clinical Trials ,
Linical Studies ,
Healthcare And Medical Technology ,
Ealth And Medical Tech ,
Ealth And Med Tech ,
Ealth And Medical Technology ,
Presection ,
Biomarker ,
Iological Marker ,
Epidermal Growth Fa ,